Related references
Note: Only part of the references are listed.Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules
Anna Gruszka et al.
ENDOCRINOLOGY (2007)
Dopamine agonists and the risk of cardiac-valve regurgitation
Rene Schade et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bromocriptine-responsive Cushing's disease; Clinical and biochemical remission accompanied by amelioration of impaired ocular movement
Mitsunobu Kawamura et al.
INTERNAL MEDICINE (2007)
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas
Dalia L. Batista et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Use of cabergoline in persisting Cushing's disease
F. Illouz et al.
ANNALES D ENDOCRINOLOGIE (2006)
PPAR-γ expression in pituitary tumours and the functional activity of the glitazones:: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor
Michelle N. Emery et al.
CLINICAL ENDOCRINOLOGY (2006)
Retinoic acid as a novel medical therapy for Cushing's disease in dogs
Victor Castillo et al.
ENDOCRINOLOGY (2006)
Therapeutic options for gastrointestinal carcinoids
Irvin M. Modlin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: Mediated through somatostatin subtype receptor 3?
WF Ruan et al.
MOLECULAR ENDOCRINOLOGY (2006)
Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease
FP Giraldi et al.
CLINICAL ENDOCRINOLOGY (2006)
Peroxisome proliferator-activated receptor (PPAR)γ is highly expressed in normal human pituitary gland
F Bogazzi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2005)
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
J van der Hoek et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Regulation of ghrelin secretion by somatostatin analogs in rats
AP Silva et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
LJ Hofland et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease
D Suri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease
B Ambrosi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma
T Miyoshi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Dopamine receptor expression and function in corticotroph pituitary tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: Evidence for direct and somatostatin-mediated effects
S Park et al.
NEUROENDOCRINOLOGY (2003)
PPAR-γ receptor ligands:: novel therapy for pituitary adenomas
AP Heaney et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas
DG Morris et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
AP Heaney et al.
NATURE MEDICINE (2002)
Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours
SRR Antonini et al.
CLINICAL ENDOCRINOLOGY (2002)
Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells
MZ Strowski et al.
NEUROENDOCRINOLOGY (2002)
Retinoic acid prevents experimental Cushing syndrome
M Páez-Pereda et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo
S Nielsen et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2001)
Dopamine D2 receptor gene expression in human adenohypophysial adenomas
L Stefaneanu et al.
ENDOCRINE (2001)
Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice
C Viollet et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates
KE Habib et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
